Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announces that it has changed its auditors from Manning Elliott LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”).  The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors […]

New Discovery

BioMark has recently completed a very encouraging metabolome study that has implication for biomarker signature related to cancer diagnosis. The discovery is being patented.

Clinical Trials – Multi Site

BioMark is proud to partner and cooperate with National Cancer Institute in Bangladesh and BioMark China in a phase III multi site trial. The trail will involve over 400 subjects and will focus on 4 cancer indications. All the procedures will follow North American regulatory guidelines that were prepared by Saint Boniface Research centre’s regulatory […]

Scientific Presentations and Publications

ACS on Campus – A panel discussion on Entrepreneurship Date: April 2/3, at UBC. ACS: American Chemical Society Rashid CEO from BioMark discussing at UBC Campus recently the opportunities and challenges of entrepuership in Canada Presentations will be made at CancerCare Manitoba by Drs. Maksymiuk, Tappia and Sitar. Presentations will be made to physicians and […]

New Scientific Advisory Board

BioMark would like to introduce and welcome 2 new members to its scientific advisory board. The new members are: Dr. Samudra Dissanayake, Director Strategic Initiatives and Business Development Health-Tech-Connex Dr. Dissanayake has been an important contributor in the development of BioMark’s technology platform for cancer screening, response to treatment and cancer treatment. Dr. Dissanayake role […]